Evommune, Inc. (EVMN) Stock Forecast & Price Target
Evommune, Inc. · NYSE
$11.21-0.26 (-2.27%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Evommune, Inc, 8 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $26.00 to $53.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $42.63 sits 280% above the current $11.21. The rating mix has stayed broadly stable, with Buy-side ratings easing from 10 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.75 next quarter toward $-3.24 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Strong Buy
Strong Buy110%
Buy770%
Hold220%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Evommune, Inc.
As of Jul, 8 of 10 firms rate EVMN a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
EVMN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.75
Range $-0.90 – $-0.67 · 8 analysts · -91% YoY
Next period, 8 analysts expect Evommune, Inc. to earn $-0.75 a share (range $-0.90 – $-0.67), versus $-8.07 a year earlier. Full-year consensus is $-2.79, growing to $-3.24 the year after.
REVENUE · NEXT QUARTER
$375.0K
Range $0 – $3.0M · 8 analysts · -96% YoY
Revenue is expected to reach $375.0K (range $0 – $3.0M), -96.3% year-over-year. Full-year consensus is $4.1M, rising to $1.3M next year.
Top analysts covering Evommune, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on EVMN.
#1
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Hold
No targeton EVMN
Overall win rate
34%
+ Follow
#2
Brian Abrahams
RBC Capital · Rank #311
Buy
$50.00+346.0% to target
Overall win rate
25%
+ Follow
#3
Judah Frommer
Morgan Stanley
Buy
$26.00+131.9% to target
Coverage
—
+ Follow
#4
KP
Kaveri Pohlman
Clear Street
Buy
$28.00+149.8% to target
Coverage
—
+ Follow
#5
MP
Matt Phipps
William Blair
Hold
No targeton EVMN
Coverage
—
+ Follow
EVMN stock forecast FAQ
What is EVMN's average 12-month price target?+
The 7 analysts with a live target average $42.63 for Evommune, Inc. over the next 12 months, ranging from a $53.00 high to a $26.00 low.
Is EVMN stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 10 analyst ratings, 8 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for EVMN?+
The Street-high target is $53.00 (Clear Street), and the Street-low is $26.00 (Morgan Stanley). The average of all 7 active targets is $42.63.
How many Wall Street analysts cover EVMN?+
10 analysts have an active rating on Evommune, Inc., and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering EVMN?+
Among analysts who currently cover EVMN, Mitchell Kapoor of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #165). Their current call is Hold.
What is Evommune, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.75 per share (range $-0.90 – $-0.67) across 8 analysts. Full-year EPS is projected at $-2.79, rising to $-3.24 the following year.
How much revenue is Evommune, Inc. expected to report next quarter?+
Consensus revenue is $375.0K (range $0 – $3.0M). Full-year revenue is projected at $4.1M, growing to $1.3M next year.
Have analysts been upgrading or downgrading EVMN lately?+
As of Jul, 8 of 10 firms rate EVMN a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their EVMN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
